Back To School
Back To School
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Bitcoin, Alkemy, Amigo, CyanConnode,
Love Hemp Group (LIFE), the CBD consumer goods company, updated regarding its Board and Management changes and the suspension of trading on the AQSE Growth Market which took place on
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is Amigo, AfriTin, Celadon, Helium One, Ironveld,
Visit here at 5 pm BST on Monday 16th May 2022 for the Pantheon Resources PLC update – Modelling Performance from Vertical to Horizontal Wells.
Hydrogen Utopia International (HUI), a company pioneering non-recyclable waste plastics to hydrogen technology, confirmed that it has been in discussions with Powerhouse Energy (PHE) on a project opportunity in The
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is Amigo, Angle, Avacta, Audioboom, Cadogan, Deltic,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection includes Amur, Amigo, Egdon, Eurasia, Evraz, GSTechnologies, Harvest, Hurricane,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection includes Amigo, Bens, Evraz, Future, i3, Jersey, Kropz, Prospex,
Oracle Power (ORCP), the international natural resources project developer, said that the drill programme over five geochemical target areas is underway at its 100% owned Jundee East Gold Project, located
BrandShield Systems (BRSD), a provider of cybersecurity solutions launched BrandShield 3.0, the ultimate solution against external digital threats such as web fraud, phishing, social media scams, impersonations and online counterfeiting.
With a mention in the Sunday Express yesterday helping along, OKYO Pharma (OKYO), a biotechnology company announced that its drug candidate OK-101 which was developed to treat DED through its